Impel Pharmaceuticals CFO Michael Kalb resigns effective Dec 31, 2023

IMPEL PHARMACEUTICALS INC

CFO Michael Kalb gave notice on Dec 1, 2023; last day is Dec 31, 2023.
Resignation not due to any disagreement with company's operations, policies, or practices.
No successor or interim CFO named; Leonard Paolillo remains Interim President & CEO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Kalb

Chief Financial Officer

IMPEL PHARMACEUTICALS INC

Effective: 2023-12-31
Filed: December 4, 2023, 6:59 PM ET

On December 1, 2023, Michael Kalb gave notice of his resignation from his position as Chief Financial Officer of Impel Pharmaceuticals Inc. (the “ Company ”) with his last day to be December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Kalb resigned as Chief Financial Officer at IMPEL PHARMACEUTICALS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On December 1, 2023, Michael Kalb gave notice of his resignation from his position as Chief Financial Officer of Impel Pharmaceuticals Inc. (the “ Company ”) with his last day to be December 31, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-287903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.